Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

In our best practices blog, we explore how lateral flow assay design affects test performance. Read on to gain a deeper understanding of the development process, enabling you to streamline the ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

The COVID-19 pandemic and geopolitical conflict in Eastern Europe have done irreparable damage to the underpinnings of the clinical diagnostic industry. These events significantly impacted the supply ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

Cancer research increasingly depends on assays that can keep pace with biological complexity, interrogating key mechanisms such as signaling pathways, enzyme activity, and cell metabolism. 1,2 As ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...

HTS is an automated experimental approach used to rapidly evaluate thousands to millions of samples—such as chemical compounds or genetic perturbations—against a defined biological target or pathway.

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

This article and associated images are based on a poster originally authored by Linda Kitching, Maxime Couturier, Jonathan Tart, Erik Elebring, Marcel Taillefer, Claudio Pathe, Giulia Bonetto, ...